cp 122288 has been researched along with Migraine Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Jandu, KS; Martin, GR; Salmon, J; Selwood, DL; Smith, D; Woollard, P | 1 |
| Johnson, KW; Phebus, LA | 1 |
| Edvinsson, L; Goadsby, PJ; Knight, YE | 1 |
| Christianssen, I; Diener, HC; Ellis, P; Ferrari, MD; Hettiarachchi, J; Kleinermans, D; Kok, JG; Olesen, J; Poole, PH; Roon, KI | 1 |
| Hargreaves, RJ; Williamson, DJ | 1 |
1 review(s) available for cp 122288 and Migraine Disorders
| Article | Year |
|---|---|
Neurogenic inflammation in the context of migraine.
Topics: Animals; Blood Proteins; Bosentan; Calcitonin Gene-Related Peptide; Capillary Permeability; Dihydroergotamine; Dura Mater; Humans; Migraine Disorders; Narcotics; Neurogenic Inflammation; Neurokinin-1 Receptor Antagonists; Pyrrolidines; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT1F; Receptors, Neurokinin-1; Receptors, Serotonin; Serotonin Receptor Agonists; Skull; Sulfonamides; Sumatriptan; Trigeminal Nerve; Vasoconstrictor Agents; Vasodilation | 2001 |
1 trial(s) available for cp 122288 and Migraine Disorders
| Article | Year |
|---|---|
No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Migraine Disorders; Neurogenic Inflammation; Placebos; Pyrrolidines; Serotonin Receptor Agonists; Sumatriptan; Treatment Failure | 2000 |
3 other study(ies) available for cp 122288 and Migraine Disorders
| Article | Year |
|---|---|
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Brain; Capillary Permeability; Cattle; CHO Cells; Cricetinae; Ear; Electric Stimulation; Guinea Pigs; Humans; In Vitro Techniques; Indoles; Male; Migraine Disorders; Models, Molecular; Oxazoles; Rabbits; Rats; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Regional Blood Flow; Serotonin Receptor Agonists; Serum Albumin, Bovine; Structure-Activity Relationship; Trigeminal Ganglion; Vasoconstrictor Agents | 2001 |
A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation.
Topics: Animals; Biological Transport; Dura Mater; Electric Stimulation; Evans Blue; Extravasation of Diagnostic and Therapeutic Materials; Fluorescence; Guinea Pigs; Inflammation; Injections, Intravenous; Male; Microscopy, Fluorescence; Microspectrophotometry; Migraine Disorders; Protein Binding; Proteins; Pyrrolidines; Sumatriptan; Trigeminal Ganglion | 1998 |
Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
Topics: Animals; Calcitonin Gene-Related Peptide; Cats; Cerebral Arteries; Cerebrovascular Circulation; Cranial Sinuses; Electric Stimulation; Indoles; Jugular Veins; Migraine Disorders; Pyrrolidines; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Trigeminal Nerve; Tryptamines | 1999 |